Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

  • End date
    Dec 1, 2025
  • participants needed
  • sponsor
    Hospital Universitario Dr. Jose E. Gonzalez
Updated on 24 October 2021
induction chemotherapy


Vinblastine can leukoreduce patients with newly diagnosed AML and hyperleukocytosis but clinical trials are lacking.


This phase 2 trial will explore the efficacy of a single dose of vinblastine (6mg/m2) to leukoreduce patients with newly diagnosed AML and hyperleukocytosis. Patients will be allocated 1:1 into two groups: intravenous single dose vinblastine or oral hydroxiurea (50mg/kg/day until response or induction chemotherapy). Effective leukoreduction and safety parameters will be compared.

Condition Acute Myelogenous Leukemia (AML), Acute Myeloid Leukemia, hyperleukocytosis, acute myelogenous leukemia, acute myeloblastic leukemia, anll, Acute myeloid leukemia
Treatment Vinblastine, Hydroxyurea capsules
Clinical Study IdentifierNCT05062278
SponsorHospital Universitario Dr. Jose E. Gonzalez
Last Modified on24 October 2021


Yes No Not Sure

Inclusion Criteria

Age >18 years
Both genders
Diagnosis of non-M3 AML by the WHO 2016 diagnostic criteria
Patients eligible and not eligible for transplant
Patients eligible and not eligible for intensive treatment
AML secondary to treatment or associated to myelodisplasia
Leukocytes 50x106/L
Not being able to receive chemotherapy in the next two days

Exclusion Criteria

AML with PMP/RAR-alfa translocation t(15;17)
Poor functional status (ECOG>2)
Active infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note